Submissions are now open to acquire a majority shareholding in Synexa Life Sciences
Clinical research companies are invited to apply to acquire a majority shareholding in a specialist biomarker services provider
05 June 2018 - 14:47
The Industrial Development Corporation (IDC) in South Africa has invited interested parties to submit an expression of interest to acquire a majority shareholding in Synexa Life Sciences from the IDC and its other shareholders. The strategic shareholder should:
be a global concern that will be able to fast-track Synexa’s global growth; be a leading clinical research company or illustrate a clear understanding of the value of biomarkers in clinical development; have a complementary strategic fit with Synexa’s biomarker activities; have sufficient capital to support rapid growth; and illustrate a history of successful growth in the biopharma market by either acquisition or trade experience...
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.